Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Westland, K. W.
Right arrow Articles by McLeod, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westland, K. W.
Right arrow Articles by McLeod, J. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 122, No. 7, 1283-1291, July 1999
© 1999 Oxford University Press

Activated non-neural specific T cells open the blood–brain barrier to circulating antibodies

K. W. Westland1, J. D. Pollard1, S. Sander1, J. G. Bonner1, C. Linington2 and J. G. McLeod1

1 Institute of Clinical Neurosciences, The University of Sydney, Sydney, Australia 2 Department of Neuroimmunology, Max Planck Institute for Psychiatry, Munich, Germany

Correspondence to: Professor J. D. Pollard, Institute of Clinical Neurosciences, University of Sydney NSW 2006, Australia

Previous studies have shown that activated T cells can successfully cross endothelial barriers and will accumulate in tissue which contains their specific antigen. Myelin specific T cells (e.g. myelin basic protein specific) are recognized to play an important role in the induction of experimental autoimmune demyelinating disease of the CNS and have been shown to induce blood–brain barrier breakdown effectively. In this study we injected T cells reactive to a non-neural antigen (ovalbumin) systemically into Lewis rats and caused them to accumulate in the thoracic dorsal column by a prior injection of ovalbumin. Selected rats were given systemic demyelinating antibody, antimyelin oligodendrocyte antibody (anti-MOG antibody), to provide evidence of permeability changes to the blood–brain barrier. These animals were compared with control rats given systemic anti-P0 monoclonal antibody and to other rats given a direct micro-injection (3 µl) of anti-MOG antibody into the thoracic dorsal column. All animals were monitored by serial neurophysiological studies and by histological examination. Direct anti-MOG antibody injection produced a focal block in conduction at the injection site and a large circumscribed area of primary demyelination with axonal preservation within the dorsal column. An even more profound conduction block and more extensive plaque-like region of demyelination were seen in animals given antigen, activated T cells and systemic antibody. However, animals given antigen and T cells without relevant antibody did not show conduction impairment or demyelination, except when very large numbers of T cells were given; such rats developed severe irreversible axonal damage. This study demonstrates the blood–brain barrier is disrupted by activated T cells of non-neural specificity and allows large plaque-like regions of demyelination to form in the presence of circulating antimyelin antibody. The relevance of this finding to multiple sclerosis is discussed.

blood–brain barrier; demyelination; activated T cell; myelin oligodendrocyte glycoprotein; conduction block

BBB = blood–brain barrier; EAE = experimental allergic encephalomyelitis; i.p. = intraperitoneal; MBP = myelin basic protein; MOG = myelin oligodendrocyte glycoprotein; PLP = proteolipid protein; SEP = sensory evoked potential


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Odoardi, N. Kawakami, W. E. F. Klinkert, H. Wekerle, and A. Flugel
Blood-borne soluble protein antigen intensifies T cell activation in autoimmune CNS lesions and exacerbates clinical disease
PNAS, November 20, 2007; 104(47): 18625 - 18630.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
N. Kawakami, U. V. Nagerl, F. Odoardi, T. Bonhoeffer, H. Wekerle, and A. Flugel
Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion
J. Exp. Med., June 6, 2005; 201(11): 1805 - 1814.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Kerschensteiner, C. Stadelmann, B. S. Buddeberg, D. Merkler, F. M. Bareyre, D. C. Anthony, C. Linington, W. Bruck, and M. E. Schwab
Targeting Experimental Autoimmune Encephalomyelitis Lesions to a Predetermined Axonal Tract System Allows for Refined Behavioral Testing in an Animal Model of Multiple Sclerosis
Am. J. Pathol., April 1, 2004; 164(4): 1455 - 1469.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
J. D. Lutton, R. Winston, and T. C. Rodman
Multiple Sclerosis: Etiological Mechanisms and Future Directions
Experimental Biology and Medicine, January 1, 2004; 229(1): 12 - 20.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. S. Heeger, T. Forsthuber, C. Shive, E. Biekert, C. Genain, H. H. Hofstetter, A. Karulin, and P. V. Lehmann
Revisiting Tolerance Induced by Autoantigen in Incomplete Freund's Adjuvant
J. Immunol., June 1, 2000; 164(11): 5771 - 5781.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. E. Juedes, P. Hjelmstrom, C. M. Bergman, A. L. Neild, and N. H. Ruddle
Kinetics and Cellular Origin of Cytokines in the Central Nervous System: Insight into Mechanisms of Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis
J. Immunol., January 1, 2000; 164(1): 419 - 426.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.